Camlin Fine Sciences Ltd

Camlin Fine Sciences Ltd

$CAMLINFINESpecialty ChemicalsNSEBSE

Camlin Fine Sciences Ltd (CAMLINFINE) last traded at ₹106, a market capitalisation of ₹2,044 crore. Over the past 52 weeks the stock has ranged between ₹96.2 and ₹235. Camlin Fine Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹520 crore and net profit of ₹-34 crore. Figures are as of 25 Aug 2026 and are not real time.

Camlin Fine Sciences Ltd share price and key metrics

Current price
₹106
Market cap
₹2,044 cr
Book value
₹54.2
ROE
3.75%
ROCE
4.78%
Dividend yield
0.00%
52w high / low
235/96.2

Metrics as of 25 Aug 2026. Not real time.

Camlin Fine Sciences Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹520 cr, up 27.5% from ₹408 cr a year earlier. Net profit was ₹-34 cr, down 209.1% year on year.

Camlin Fine Sciences Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales417431432408460441425520
Expenses366375370387427420404511
Operating profit525662203321219
OPM %12%13%14%5.0%7%4.7%5.0%1.8%
Other income-151-8-22-0-4-24103-10
Interest2634151519172314
Depreciation1714171619162119
Profit before tax-142-08-11-9-3780-34
Tax %-18%2,164%98%-0%65%-0%-8%-1%
Net profit-116-70-11-15-3786-34
EPS (₹)-5.33-0.22-0.04-0.53-0.76-1.894.59-1.65

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Camlin Fine Sciences Ltd annual results

Camlin Fine Sciences Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,1871,4121,6821,4541,6291,7231,845
Operating profit18715821117022711884
OPM %16%11%13%12%14%7%4.6%
Net profit656040-105-158241
EPS (₹)3.563.452.96-4.94-7.401.440.29

TTM is the trailing twelve months to the most recent quarter.

Camlin Fine Sciences Ltd growth and returns

Compounded Sales Growth
10 Years
13%
5 Years
8%
3 Years
1%
TTM
9%
Compounded Profit Growth
10 Years
-1%
5 Years
-6%
3 Years
-14%
TTM
-139%
Stock Price CAGR
10 Years
2%
5 Years
-8%
3 Years
-11%
1 Year
-52%
Return on Equity
10 Years
-1%
5 Years
-2%
3 Years
-7%
Last Year
4%

Camlin Fine Sciences Ltd shareholding pattern

Promoters held 48.03% at Jun 2026, down from 49.09% at Jun 2025. FIIs 0.91% and DIIs 5.42%.

Camlin Fine Sciences Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters48.03%48.03%49.09%49.09%49.08%48.03%48.03%48.03%
FIIs0.81%0.76%1.47%2.88%2.11%2.12%0.94%0.91%
DIIs4.23%3.38%3.83%4.14%5.48%7.77%7.70%5.42%
Public46.93%47.83%45.61%43.88%43.33%42.07%43.31%45.63%
No. of shareholders67,75061,89358,11159,53857,66152,35752,23255,178

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Camlin Fine Sciences Ltd corporate filings

  • Transcript of the Earnings Call Q1FY27Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences reported Q1 FY27 revenue of INR519.9 crore, reflecting a 28% YoY…

    Read the full analysis
  • Newspaper Publication - Unaudited Financial Results for the quarter ended June 30, 2026.Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited reported its financial results for the quarter ended June…

    Read the full analysis
  • Investor Call Recording Q1 FY27Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Ltd has filed the audio recording of its Q1 FY27 investor conference…

    Read the full analysis
  • Investor Presentation Q1 FY27Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited reported Q1 FY27 revenue of 519.8 crore, a 27.5% YoY…

    Read the full analysis
  • Un-audited Financial Results for the quarter ended June 30, 2026Resulthigh impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited reported a consolidated net loss of 33.62 crore for the…

    Read the full analysis
  • Proceedings of the 33rd AGMAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited has successfully concluded its 33rd Annual General Meeting…

    Read the full analysis
  • Schedule of Investor Meet - Q1FY27 Earnings CallCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited announced it will host a conference call with various…

    Read the full analysis
  • Camlin Fine Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-audited Standalone ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Camlin Fine Sciences Limited announced a board meeting scheduled for August 11, 2026, to…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Camlin Fine Sciences Ltd

Cruxal reads every Camlin Fine Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.